Short Interest in Tivic Health Systems, Inc. (NASDAQ:TIVC) Declines By 32.7%

by · The Cerbat Gem

Tivic Health Systems, Inc. (NASDAQ:TIVC – Get Free Report) was the target of a significant decrease in short interest in the month of October. As of October 31st, there was short interest totalling 111,300 shares, a decrease of 32.7% from the October 15th total of 165,300 shares. Currently, 1.8% of the shares of the company are sold short. Based on an average daily volume of 5,120,000 shares, the short-interest ratio is currently 0.0 days.

Hedge Funds Weigh In On Tivic Health Systems

An institutional investor recently bought a new position in Tivic Health Systems stock. Warberg Asset Management LLC bought a new stake in shares of Tivic Health Systems, Inc. (NASDAQ:TIVC – Free Report) during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 80,000 shares of the company’s stock, valued at approximately $31,000. Warberg Asset Management LLC owned approximately 1.29% of Tivic Health Systems at the end of the most recent reporting period. 4.25% of the stock is owned by hedge funds and other institutional investors.

Tivic Health Systems Price Performance

Shares of NASDAQ TIVC traded down $0.08 during midday trading on Friday, reaching $0.29. 2,159,292 shares of the stock were exchanged, compared to its average volume of 3,192,011. The firm has a 50-day simple moving average of $0.28 and a two-hundred day simple moving average of $0.39. Tivic Health Systems has a twelve month low of $0.22 and a twelve month high of $3.21.

Tivic Health Systems (NASDAQ:TIVC – Get Free Report) last posted its earnings results on Wednesday, August 14th. The company reported ($0.32) earnings per share (EPS) for the quarter. Tivic Health Systems had a negative return on equity of 172.08% and a negative net margin of 606.47%. The firm had revenue of $0.14 million for the quarter.

About Tivic Health Systems

(Get Free Report)

Tivic Health Systems Inc operates as a health tech company, focuses on developing and commercializing bioelectronic medicine. Its primary product is ClearUP, a bioelectronic medicine for the treatment of sinus and nasal inflammation. The company sells its products on direct-to-consumer channel through its own websites; and platforms, such as Amazon.com and Walmart.com, as well as to U.S.

Read More